Table 1.
Details of 164 randomised placebo controlled trials of statins and serum cholesterol reduction. Figures are means (90% range) unless stated otherwise
| Treatment | Placebo | |
|---|---|---|
| No of treatment groups (participants) in trials of: | ||
| Atorvastatinw1-w15 | 24 (2217) | 15* (2051) |
| Fluvastatinw16-w38 | 31 (3054) | 23 (1675) |
| Lovastatinw14 w39-w52 | 28 (7938) | 15 (2710) |
| Pravastatinw14 w52-w120 | 85 (5474) | 70 (4382) |
| Rosuvastatinw2 w121 | 9 (394) | 2 (161) |
| Simvastatinw14 w15 w16-w120 w122-w164 | 72 (4906) | 50 (3933) |
| All trials | 249 (23983) | 164† (14320) |
| No of participants per treatment group | 95 (8-396) | 87 (7-412) |
| No of treatment arms per design: | ||
| Crossover | 42 | 33 |
| Parallel groups | 207 | 131 |
| Serum cholesterol (mmol/l) concentrations before treatment:
|
|
|
| Total cholesterol | 6.8 (5.6-9.9) | 6.7 (5.3-9.5) |
| LDL cholesterol | 4.8 (3.2-7.4) | 4.6 (3.0-6.8) |
| Median duration (weeks) | 8 (4-48) | 8 (4-48) |
| Age (years) | 55 (43-71) | 55 (43-70) |
*
Number of placebo groups is same as number of trials.
†
Less than total of five categories because some trials compared two or more statins with same placebo group.